Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279937 · ClinicalTrials.gov registry record · Phase 3
The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients
A Phase 3 study, sponsored by Tulane University.
- Not yet
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT05279937 is a Phase 3 study that has not yet begun recruiting, run by Tulane University. The registered enrollment target is 40 participants.
The verdict
NCT05279937, a Phase 3 study, has not yet begun recruiting, sponsored by Tulane University.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
1. Specific Aim: To show the safety and efficacy of prolotherapy injection for chronic sacroiliac and myofascial lumbar pain while standardizing an ultrasound guided injection technique 2. Specific Aim: To demonstrate that dextrose prolotherapy subjectively decreases lumbar back pain (LBP) associated with chronic sacroiliac (SI) and myofascial lumbar back pain/injury in patients with Hypermobile-Type Ehlers-Danlos Syndrome (hEDS). 3. Specific Aim: To use ultrasound (US) guidance to identify SI and myofascial lumbar back pain/injury for targeted dextrose prolotherapy treatment and to provide objective measures of decreasing inflammation via Power Doppler and ligament repair. 4. Specific Aim: To determine if US-guided dextrose prolotherapy decreases the direct costs of care for chronic LBP in contrast to conventional therapies by reducing return visits, specialty referrals, physical therapy, medications, and unnecessary procedures.
Interventions
- DRUG Lidocaine 1% Injectable Solution
- DRUG Dextrose 50% Intravenous Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279937
The ClinicalTrials.gov registry entry for NCT05279937 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lidocaine 1% Injectable Solution is the first listed.
NCT05279937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05279937 about?
NCT05279937 is a clinical study titled "The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients". 1. Specific Aim: To show the safety and efficacy of prolotherapy injection for chronic sacroiliac and myofascial lumbar pain while standardizing an ultrasound guided injection technique 2. Specific Aim: To demonstrate that dextrose prolotherapy subjectively decreases lumbar back pain (LBP) associate...
What is the current status of trial NCT05279937?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2026-06. Estimated completion is 2027-06.
What interventions are being tested in trial NCT05279937?
The interventions under investigation include: Lidocaine 1% Injectable Solution (DRUG), Dextrose 50% Intravenous Solution (DRUG).
Who is sponsoring clinical trial NCT05279937?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.